JP7734587B2 - 皮膚エリテマトーデスの治療 - Google Patents

皮膚エリテマトーデスの治療

Info

Publication number
JP7734587B2
JP7734587B2 JP2021562843A JP2021562843A JP7734587B2 JP 7734587 B2 JP7734587 B2 JP 7734587B2 JP 2021562843 A JP2021562843 A JP 2021562843A JP 2021562843 A JP2021562843 A JP 2021562843A JP 7734587 B2 JP7734587 B2 JP 7734587B2
Authority
JP
Japan
Prior art keywords
compound
lupus erythematosus
formula
pharmaceutical formulation
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021562843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533526A (ja
Inventor
ニールセン，ヤコブ
ポマーゴー ペーダセン，ギッテ
モーテンセン，ヘレーネ
サンダー，カミラ
クリー リファー，ピア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of JP2022533526A publication Critical patent/JP2022533526A/ja
Priority to JP2025080666A priority Critical patent/JP2025114800A/ja
Application granted granted Critical
Publication of JP7734587B2 publication Critical patent/JP7734587B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021562843A 2019-05-15 2020-05-14 皮膚エリテマトーデスの治療 Active JP7734587B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025080666A JP2025114800A (ja) 2019-05-15 2025-05-13 皮膚エリテマトーデスの治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19174586 2019-05-15
EP19174586.8 2019-05-15
PCT/EP2020/063518 WO2020229622A1 (en) 2019-05-15 2020-05-14 Treatment of cutaneous lupus erythematosus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025080666A Division JP2025114800A (ja) 2019-05-15 2025-05-13 皮膚エリテマトーデスの治療

Publications (2)

Publication Number Publication Date
JP2022533526A JP2022533526A (ja) 2022-07-25
JP7734587B2 true JP7734587B2 (ja) 2025-09-05

Family

ID=66554234

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021562843A Active JP7734587B2 (ja) 2019-05-15 2020-05-14 皮膚エリテマトーデスの治療
JP2025080666A Pending JP2025114800A (ja) 2019-05-15 2025-05-13 皮膚エリテマトーデスの治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025080666A Pending JP2025114800A (ja) 2019-05-15 2025-05-13 皮膚エリテマトーデスの治療

Country Status (15)

Country Link
US (2) US20220241284A1 (https=)
EP (1) EP3968997B1 (https=)
JP (2) JP7734587B2 (https=)
KR (1) KR20220008893A (https=)
CN (1) CN113825512A (https=)
AU (1) AU2020275208B2 (https=)
BR (1) BR112021022031A2 (https=)
CA (1) CA3137247A1 (https=)
IL (1) IL288011A (https=)
MX (1) MX2021012874A (https=)
SG (1) SG11202110777XA (https=)
TW (1) TWI863995B (https=)
UA (1) UA129431C2 (https=)
WO (1) WO2020229622A1 (https=)
ZA (1) ZA202107300B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202989A1 (en) 2022-04-20 2023-10-26 Leo Pharma A/S Treatment of frontal fibrosing alopecia
WO2024194105A1 (en) * 2023-03-17 2024-09-26 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513058A (ja) 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
JP2019502734A (ja) 2016-01-21 2019-01-31 レオ ファーマ アクティーゼルスカブ 手湿疹の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8883838B2 (en) * 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
PT3297605T (pt) * 2015-05-21 2022-05-30 Dermavant Sciences GmbH Composições farmacêuticas tópicas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513058A (ja) 2003-09-08 2007-05-24 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
US20180264080A1 (en) 2015-01-09 2018-09-20 Kineta One, Llc TOPICAL APPLICATIONS OF Kv1.3 CHANNEL BLOCKING PEPTIDES TO TREAT SKIN INFLAMMATION
JP2019502734A (ja) 2016-01-21 2019-01-31 レオ ファーマ アクティーゼルスカブ 手湿疹の治療

Also Published As

Publication number Publication date
AU2020275208A1 (en) 2021-10-28
UA129431C2 (uk) 2025-04-23
JP2025114800A (ja) 2025-08-05
KR20220008893A (ko) 2022-01-21
CN113825512A (zh) 2021-12-21
EP3968997B1 (en) 2026-03-18
EP3968997A1 (en) 2022-03-23
BR112021022031A2 (pt) 2021-12-28
AU2020275208B2 (en) 2025-12-04
US20260069595A1 (en) 2026-03-12
TWI863995B (zh) 2024-12-01
WO2020229622A1 (en) 2020-11-19
CA3137247A1 (en) 2020-11-19
TW202106690A (zh) 2021-02-16
JP2022533526A (ja) 2022-07-25
SG11202110777XA (en) 2021-11-29
MX2021012874A (es) 2021-11-17
US20220241284A1 (en) 2022-08-04
IL288011A (en) 2022-01-01
ZA202107300B (en) 2025-12-17

Similar Documents

Publication Publication Date Title
JP2025114800A (ja) 皮膚エリテマトーデスの治療
AU2022252766B2 (en) Treatment of hand eczema
WO2023202989A1 (en) Treatment of frontal fibrosing alopecia
TWI720022B (zh) 圓禿之新穎治療
RU2847397C2 (ru) Лечение кожной формы красной волчанки
HK40063225A (en) Treatment of cutaneous lupus erythematosus
HK40102338A (en) Treatment of hand eczema
HK1260652B (en) Use of delgocitinib for the treatment of chronic hand eczema
HK1260652A1 (en) Use of delgocitinib for the treatment of chronic hand eczema

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230508

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240918

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250513

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250826

R150 Certificate of patent or registration of utility model

Ref document number: 7734587

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150